Evidence map›Paper›PMID 26124787›Full record

ArticleAfrican health sciences2015

Response of patent medicine vendors in rural areas of Lagos state Nigeria to antimalarial policy change.

Abisoye Oyeyemi, Babatunde Ogunnowo, Oluwakemi Odukoya

Open access · diamondAbstract read
In one paragraph

Article in African health sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Malaria Knowledge and Treatment Practices in Enugu State, Nigeria: A Qualitative Study.International journal of health policy and management · 2018
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Abisoye OyeyemiDepartment of Community Medicine, Faculty of Clinical Sciences, College of Health Sciences, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria.
Babatunde OgunnowoDepartment of Community Health and Primary Care, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria.
Oluwakemi OdukoyaDepartment of Community Health and Primary Care, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria.
University of Lagos · NGNiger Delta University · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatent medicine vendors (PMVs) play an important role in the treatment of malaria, especially in the rural areas. Nigeria recently changed her antimalarial treatment policy from chloroquine to artemisinin-based combination therapy (ACT).

objectivesTo determine the response of PMVs to the new policy.

methodsA baseline study was conducted in two local government areas (LGAs) of Lagos state Nigeria as the first phase in an intervention study aimed at improving the malarial treatment practices of PMVs in rural Lagos. A mixed method design involving a questionnaire survey of 180 PMVs and four key informant interviews were used. An antimalarial drug (AMD) audit was also performed.

resultsMore than 80% of respondents were aware of the policy change in malaria treatment, but only 23.9% sold an ACT for the last case of malaria treated in an under five child. The main determining factor of the particular AMD sold was PMV's personal choice (70.6%). About half (58.9%) of the shops stocked ACTs, the newly recommended antimalarials.

conclusionsThe high awareness of the policy change did not translate to a commensurate increase in the sale of the new drugs. Factors beyond the PMVs need to be addressed for a successful adoption of the new policy.

Indexed as

CommerceHealth PolicyAntimalarialsArtemisininsChloroquineHealth SurveysHumansInterviews as TopicMalariaNigeriaNonprescription DrugsRural PopulationSurveys and QuestionnairesAntimalarialsArtemisininsChloroquineNonprescription DrugsACTsartemisinin monotherapiesmalarianon-artemisinin therapiesPatent Medicine Vendorspolicy change

Identifiers

PMID26124787
PMCPMC4480472
OpenAlexW1592358290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.